Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Friday 01 June, 2018

AstraZeneca PLC

Director Declaration

RNS Number : 0227Q
AstraZeneca PLC
01 June 2018
 

01 June 2018 11:00 BST

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Sheri McCoy, a Non-Executive Director of the Company, was appointed as a director of NovoCure Limited following the conclusion of its Annual General Meeting of Shareholders with effect from 31 May 2018.

 

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations

 

 

Gonzalo Viña

UK/Global

+44 203 749 5916

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Karen Birmingham

UK/Global

+44 203 749 5634

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Relations

 

 

Thomas Kudsk Larsen

 

 

+44 203 749 5712

Josie Afolabi

 

+44 7970 620 449

Craig Marks

Finance; Fixed Income; M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Jennifer Kretzmann 

Retail investors 

+44 203 749 5824

US toll free

 

+1 866 381 7277

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RDNKFLBBVQFEBBE

a d v e r t i s e m e n t